Search

Search Results

1. Multiple Myeloma

   The concept of high-dose therapy (HDT) followed by autologous hematopoietic cell transplantation (AHCT) remains the standard for treating newly...

   Mohamad Mohty, Benedetto Bruno, ... Maria-Victoria Mateos in The EBMT Handbook

   Chapter Open access 2024
   

2. Tumors: Multiple Myeloma

   Multiple myeloma is characterized by the malignant proliferation of plasma cells, causing extensive skeletal osteolytic destruction, osteopenia, and...

   Tim Van den Wyngaert in Clinical Atlas of Bone SPECT/CT

   Living reference work entry 2023
   

3. Tumors: Multiple Myeloma

   Multiple myeloma is characterized by the malignant proliferation of plasma cells, causing extensive skeletal osteolytic destruction, osteopenia, and...

   Tim Van den Wyngaert in Clinical Atlas of Bone SPECT/CT

   Reference work entry 2023
   

4. Plasma Cell Myeloma/Multiple Myeloma

   Plasma cells are a type of white blood cells derived from mature B-lymphocytes in the bone marrow, which play an important role in protecting the...

   Won-Jong Bahk in Diagnosis and Management of Primary Bone Tumors

   Chapter 2023
   

5. Introduction to Multiple Myeloma and Multiple Myeloma Bone Disease

   Multiple myeloma (MM) is a malignant disease characterized by proliferation of clonal plasma cells that are derived from post-germinal center B...

   Naseem Shams Esteghamat, Mehrdad Abedi in Metastatic Bone Disease

   Chapter 2024
   

6. Immunotherapy for Multiple Myeloma

   Multiple myeloma is a clonal disorder of bone marrow plasma cells. Despite the impressive advances in treatment options in the last two decades,...

   Anthony Oyekunle in Handbook of Cancer and Immunology

   Living reference work entry 2023
   

7. Side Effects of Treatment in Multiple Myeloma

   The treatment of multiple myeloma has evolved impressively over the last two decades. Conventional chemotherapy has nowadays been largely replaced by...

   Michel Delforge in Side Effects of Cancer Therapy

   Living reference work entry 2024
   

8. Multiple myeloma

   Multiple myeloma (MM) is a haematological lymphoid malignancy involving tumoural plasma cells and is usually characterized by the presence of a...

   Florent Malard, Paola Neri, ... Mohamad Mohty in Nature Reviews Disease Primers

   Article 27 June 2024
   

9. Multiple Myeloma

   in Dictionary of Toxicology

   Reference work entry 2024
   

10. Multiple Myeloma

    Multiple myeloma is a neoplastic disorder of plasma cells. A plasma cell is a terminally differentiated B-lymphocyte able to produce antibodies or...

    Rami Kotb, Caroline Hart, Hadi Goubran in Paraproteinemia and Related Disorders

    Chapter 2022
    

11. Orbital Multiple Myeloma

    Key features of orbital multiple myeloma (MM):...

    Jaskirat Aujla, Valerie Juniat, ... Dinesh Selva in Atlas of Orbital Imaging

    Reference work entry 2022
    

12. Multiple Myeloma Misdiagnosed as Rheumatoid Arthritis

    Hematopoietic cancers (HCs), more commonly called blood cancers, are the malignancies of the hematopoietic stem cells. They are commonly caused by or...

    Safeera Khan, Junaid Hassan in The Misdiagnosis Casebook in Clinical Medicine

    Chapter 2023
    

13. Selenoprotein W engages in overactive osteoclast differentiation in multiple myeloma

    Background

    Patients with multiple myeloma exhibit malignant osteolytic bone disease due to excessive osteoclast formation and function. We recently...

    Hyunsoo Kim, Jiin Oh, ... Daewon Jeong in Molecular Biology Reports

    Article Open access 29 April 2024
    

14. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth

    Anti-multiple myeloma B cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapies represent a promising treatment...

    Fumou Sun, Yan Cheng, ... Fenghuang Zhan in Nature Communications

    Article Open access 19 January 2024
    

15. Personalized Treatment of Multiple Myeloma in Frail Patients

    Purpose of Review

    As the treatment landscape for multiple myeloma (MM) continues to expand at a rapid pace, management of older adults and frail...

    Jodi J. Lipof, Nadine Abdallah, Brea Lipe in Current Oncology Reports

    Article 18 May 2024

16. Assessment tools for patient-reported outcomes in multiple myeloma

    Background

    Patients with multiple myeloma experience severe symptom burden. Patient participation in self-reporting is essential as medical staff’s...

    Ting Wang, Qin Lu, LeiWen Tang in Supportive Care in Cancer

    Article Open access 30 June 2023

17. CAR T therapies in multiple myeloma: unleashing the future

    In recent years, the field of cancer treatment has witnessed remarkable breakthroughs that have revolutionized the landscape of care for cancer...

    Mohsen Sheykhhasan, Amirhossein Ahmadieh-Yazdi, ... Paola Dama in Cancer Gene Therapy

    Article Open access 04 March 2024
    

18. Plasma Cell Dyscrasias: Multiple Myeloma and Precursors

    Multiple myeloma is a plasma cell dyscrasia that affects primarily the bone marrow by infiltration and replacement of normal hematopoietic marrow....

    Andrea Baur-Melnyk, Thomas Van Den Berghe, Koenraad Verstraete in Musculoskeletal Imaging

    Living reference work entry 2023
    

19. ASH highlights 2022—multiple myeloma

    The 64th annual meeting was held in New Orleans, Louisiana from December 10–13, 2022. More than 150 abstracts concerning multiple myeloma have been...

    Lina Z. Rüsing, Hermine Agis, Maria Krauth in memo - Magazine of European Medical Oncology

    Article Open access 22 July 2023

20. Rheological properties of blood in multiple myeloma patients

    Multiple myeloma (MM) is considered to be one of the hematological malignancies formed by excessive and abnormal proliferation of plasmocytes. Among...

    Bartłomiej Ptaszek, Szymon Podsiadło, ... Olga Czerwińska-Ledwig in Scientific Reports

    Article Open access 21 February 2024